China Pharma Holdings (CPHI) Accumulated Expenses (2010 - 2026)
China Pharma Holdings (CPHI) posted Accumulated Expenses of $311336.0 for Q1 2026, down 11.21% on a QoQ basis from $350643.0 in Q4 2025, and down 80.49% year-over-year from $1.6 million in Q1 2025.
China Pharma Holdings (CPHI) Accumulated Expenses (2010 - 2026) Analysis & Trends
China Pharma Holdings' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $311336.0 for Q1 2026.
- Quarterly Accumulated Expenses fell 80.49% year-over-year to $311336.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311336.0 (down 80.49% YoY) and the FY2025 annual result came in at $350643.0, up 41.87% from the prior year.
- Accumulated Expenses was $311336.0 for Q1 2026 at China Pharma Holdings, down from $350643.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.6 million in Q3 2025 and bottomed at $110387.0 in Q2 2022.
- A 5-year average of $486814.0 and a median of $208831.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses soared 1291.8% — and 2026, when it slumped 80.49%.
- China Pharma Holdings' Accumulated Expenses stood at $404807.0 in 2022, then jumped by 210.15% to $1.3 million in 2023, then sank by 80.31% to $247159.0 in 2024, then surged by 41.87% to $350643.0 in 2025, then declined by 11.21% to $311336.0 in 2026.
- Business Quant data shows CPHI's Accumulated Expenses at $311336.0 in Q1 2026, $350643.0 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 311,336.00 |
| Dec 31, 2025 | 350,643.00 |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 191,293.00 |
| Mar 31, 2025 | 1.60 Mn |
| Dec 31, 2024 | 247,159.00 |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 208,831.00 |
| Mar 31, 2024 | 114,636.00 |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 119,669.00 |
| Jun 30, 2023 | 120,563.00 |
| Mar 31, 2023 | 113,750.00 |
| Dec 31, 2022 | 404,807.00 |
| Sep 30, 2022 | 126,519.00 |
| Jun 30, 2022 | 110,387.00 |
| Mar 31, 2022 | 138,221.00 |
| Dec 31, 2021 | 298,452.00 |
| Sep 30, 2021 | 227,416.00 |
| Jun 30, 2021 | 332,393.00 |